IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8 by Sanchez-Fernandez, Alba et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-02 and may be subject to
change.






2021; 11(1): 1-13. doi: 10.7150/thno.47435 
Research Paper 
IL-37 exerts therapeutic effects in experimental 
autoimmune encephalomyelitis through the receptor 
complex IL-1R5/IL-1R8 
Alba Sánchez-Fernández1,2, Stephanie Zandee3, Jesús Amo-Aparicio1,2, Marc Charabati3, Alexandre Prat3, 
Cecilia Garlanda4, Elan Z. Eisenmesser5, Charles A. Dinarello6,7 and Rubèn López-Vales1,2 
1. Institut de Neurociencies and Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autonoma de Barcelona, Bellaterra, Catalonia, Spain. 
2. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED). 
3. Department of Neuroscience, Faculty of Medicine, Université de Montréal, and Neuroimmunology Unit, Centre de Recherche du CHUM (CRCHUM), Montréal, 
Québec, Canada. 
4. Humanitas Clinical and Research Center, 20089 Rozzano, Italy. 
5. Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, CO 80238, USA. 
6. Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA. 
7. Department of Medicine, Radboud University Medical Center, 6500 Nijmegen, The Netherlands. 
 Corresponding author: Prof. Rubèn López-Vales, Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain. E-mail: ruben.lopez@uab.cat. 
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). 
See http://ivyspring.com/terms for full terms and conditions. 
Received: 2020.04.25; Accepted: 2020.08.23; Published: 2021.01.01 
Abstract 
Background: Interleukin 37 (IL-37), a member of IL-1 family, broadly suppresses inflammation in many 
pathological conditions by acting as a dual-function cytokine in that IL-37 signals via the extracellular receptor 
complex IL1-R5/IL-1R8, but it can also translocate to the nucleus. However, whether IL-37 exerts beneficial 
actions in neuroinflammatory diseases, such as multiple sclerosis, remains to be elucidated. Thus, the goals of 
the present study were to evaluate the therapeutic effects of IL-37 in a mouse model of multiple sclerosis, and 
if so, whether this is mediated via the extracellular receptor complex IL-1R5/IL-1R8. 
Methods: We used a murine model of MS, the experimental autoimmune encephalomyelitis (EAE). We 
induced EAE in three different single and double transgenic mice (hIL-37tg, IL-1R8 KO, hIL-37tg-IL-1R8 KO) 
and wild type littermates. We also induced EAE in C57Bl/6 mice and treated them with various forms of 
recombinant human IL-37 protein. Functional and histological techniques were used to assess locomotor 
deficits and demyelination. Luminex and flow cytometry analysis were done to assess the protein levels of 
pro-inflammatory cytokines and different immune cell populations, respectively. qPCRs were done to assess 
the expression of IL-37, IL-1R5 and IL-1R8 in the spinal cord of EAE, and in blood peripheral mononuclear cells 
and brain tissue samples of MS patients. 
Results: We demonstrate that IL-37 reduces inflammation and protects against neurological deficits and 
myelin loss in EAE mice by acting via IL1-R5/IL1-R8. We also reveal that administration of recombinant human 
IL-37 exerts therapeutic actions in EAE mice. We finally show that IL-37 transcripts are not up-regulated in 
peripheral blood mononuclear cells and in brain lesions of MS patients, despite the IL-1R5/IL-1R8 receptor 
complex is expressed. 
Conclusions: This study presents novel data indicating that IL-37 exerts therapeutic effects in EAE by acting 
through the extracellular receptor complex IL-1R5/IL-1R8, and that this protective physiological mechanism is 
defective in MS individuals. IL-37 may therefore represent a novel therapeutic avenue for the treatment of MS 
with great promising potential. 
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Introduction 
Multiple sclerosis (MS) is the most common 
demyelinating disease of the central nervous system 
(CNS) and affects more than 2.5 million individuals 
worldwide [1]. Although its aetiology remains 
complex, MS is thought to be autoimmune in nature 









autoantibodies in the cerebrospinal fluid of MS 
patients [2–5]. Therefore, blocking inflammation will 
likely be therapeutically beneficial for treating MS 
patients. 
The IL-1 family includes prototypic cytokines 
that promote acute and chronic inflammation in a 
broad spectrum of diseases [6, 7]. Seven of the 11 
members exhibit pro-inflammatory properties, 
whereas four members reduce inflammation [8]. Of 
these four, IL-37 broadly suppresses innate as well as 
adaptive immunity [8–10]. 
The IL-37 gene is composed by 6 exons that give 
rise to five different isoforms (IL-37a to IL-37e) [11, 
12]. However, only the isoforms a, b and d are 
functional since, contrary to the isoforms c and e, they 
have the presence of the complete sequence encoding 
the 12β-strands structure and at least one cleavage site 
required for the maturation of the cytokine [13]. 
Among them, IL-37b (isoform 1) is the longer isoform 
and it is the one that has been used in experimental 
studies for its functional characterization [11]. 
IL-37 exert anti-inflammatory actions by acting 
as a ligand for the extracellular receptor complex 
comprised of IL-1R5 (IL-18Rα) and the co-receptor, 
IL-1R8 [14]. Similar to IL-1α and IL-33, intracellular 
IL-37 translocates to the nucleus via caspase-1 
cleavage and binding to SMAD3 [13, 15]. 
Unlike other members of the IL-1 family, the 
open read frame for the IL-37 homolog is lacking in 
mice. To investigate the role IL-37 in animal models of 
human diseases, it was thus necessary to generate a 
knock-in mouse expressing human IL37b (hIL-37tg) 
1[6]. hIL-37tg mice have demonstrated resistance 
against many pathological conditions, such as 
systemic endotoxemia [9], colitis [17] and obesity- 
induced inflammation [18]. In parallel, treatment with 
recombinant human IL-37 protein improved 
aspergillosis [19] and rheumatoid arthritis [19, 20] by 
exerting its anti-inflammatory properties. 
Little is known about the role of IL-37 in the 
central nervous system. We previously reported that 
IL-37 exerts marked anti-inflammatory effects after 
spinal cord contusion injury in mice. Notably, 
hIL-37tg mice displayed significant resistance against 
functional deficits and demyelination after spinal cord 
injury (SCI) [21]. A recent report reveals that IL-37 is 
reduced in blood leukocytes of multiple sclerosis (MS) 
[22], suggesting that this anti-inflammatory pathway 
might be defective in MS. However, whether IL-37 
has similar therapeutic effects in neuroinflammatory 
conditions, such as MS, has not been addressed yet. 
In the present study, we investigated the 
anti-inflammatory and therapeutic potential of IL-37 
in experimental autoimmune encephalomyelitis 
(EAE), a mouse model of MS. We demonstrate that 
the transgenic expression of human IL-37 mediates 
broad anti-inflammatory effects in EAE and protects 
mice from the functional deficits and demyelination. 
Furthermore, we show that the beneficial effects of 
IL-37 in EAE are dependent on its extracellular 
receptor function. Relevant to the studies in mice, we 
discovered that this natural anti-inflammatory 
mechanism is deficient in blood and brain active 
lesions of MS patients. Lastly, we provide clear 
evidence that the administration of recombinant 
human IL-37 protein markedly reduces EAE 
pathogenesis. Altogether, our findings reveal that 
IL-37 could be employed as a new approach for the 
treatment of MS. 
Materials and Methods 
MS brain tissue samples 
Human brain tissue was obtained from MS 
patients diagnosed with clinical and neuro-
pathological MS diagnosis according to the revised 
2010 McDonald’s criteria [23]. Tissue samples were 
collected from MS patients with full ethical approval 
(BH07.001) and informed consent as approved by the 
local ethics committee. Autopsy samples were 
cryopreserved and lesions classified using Luxol Fast 
Blue (LFB)/Haematoxylin & Eosin staining and Oil 
Red O staining as previously published [24, 25]. 
Normal appearing white matter (NAWM) and active 
lesions representing two relapsing-remitting MS 
(RRMS) (one male and one female) and seven 
secondary-progressive MS (SPMS) (three males and 
four females) were used (Table S1). The median age at 
death was 50 years (range from 26 to 65 years). 
Regions of interest (active lesion or NAWM) for RNA 
isolation were manually dissected from 5-6 
cryosections per block (50 μm width). 
MS and healthy donor PBMC samples 
Blood samples were collected from the following 
subjects: three from patients with secondary 
progressive (SPMS) (one male and two females), and 
eight from patients with relapsing-remitting MS 
(RRMS) (three males and eight females) (Table S1). All 
patients were recruited at the MS Clinic at the 
Research Center of the University of Montreal 
Hospital Center (CRCHUM). Their ages ranged from 
27 to 65 years (mean age, 43 years). At time of blood 
sampling, only two patients were receiving treatment 
with disease modifying drugs (Table S1). Seven 
healthy volunteers were included as controls (four 
males and three females); their ages ranged from 24 to 
42 years (mean age, 35 years). A written informed 
consent was obtained from patients and healthy 
donors in accordance with the local ethics committee 
(CRCHUM research ethic committee approval 





number BH07.001). PBMCs were isolated from blood 
samples collected in EDTA-coated vacutainer tubes 
(BD Biosciences, Oakville, ON, Canada) using a Ficoll 
density gradient (Amersham Biosciences) as 
described previously [26, 27]. 
Mice 
All experimental procedures were approved by 
the Universitat Autònoma de Barcelona Animal 
Experimentation Ethical Committee (CEEAH 2878) 
and followed the European Communities Council 
Directive 2010/63/EU, and the methods were carried 
out in accordance with the approved guidelines. 
Experiments were performed in adult (8-10 
weeks) female or male C57Bl/6 mice (Charles River), 
transgenic mice homozygote for human IL-37b (hIL- 
37tg), Il1r8 deficient mice (Il1r8 KO), hIL-37tg-Sigirr 
KO mice, and their respective wildtype littermates. 
Mice were randomly distributed in groups of 5-6 mice 
per cage. All mice were housed with food and water 
ad libitum at room temperature of 22±2ºC under 12:12 
h light-dark cycle. 
EAE induction 
Mice were sedated with intramuscular injection 
of mixture of ketamine (22 mg/kg) (Imalgen 1000, 
Merial) and xylazine (2.5 mg/kg) (Rompun, Bayer). 
EAE was actively induced by subcutaneously 
injection in each flank at the base of the tail of 100 µl of 
3 mg/mL of myelin oligodendrocyte glycoprotein 
peptide 35-55 (MOG35-55) in Complete Freund’s 
Adjuvant (CFA) (Difco, Detroit, MI, USA) 
supplemented with 4mg/mL of heat inactivated 
Mycobacterium tuberculosis (Difco, Detroit, MI, USA). 
Immediately after induction, and on day 2, mice 
received an intraperitoneal (i.p.) injection of 400 ng of 
pertussis toxin (PTX) in 100 µl sterile saline (0.9% 
NaCl). 
Functional evaluation of EAE mice 
Mice were scored daily from day 0 to day 21 
after induction of EAE. The researcher was blinded to 
experimental groups during the functional 
evaluation. A 6-point scale was used to evaluate the 
clinical signs of EAE: 0 = normal walking; 0.5 = 
partially paralyzed tail; 1 = fully paralyzed tail; 2 = 
mild hind limb weakness, quick righting reflex; 3 = 
severe hind limb weakness, slow righting reflex, 
unable to bear weight; 3.5 = severe hind limb 
weakness and partial paralysis of hind limb; 4 = 
complete paralysis of at least one hind limb; 4.5 = 
complete paralysis of one or both hind limbs and 
trunk weakness; 5 = complete paralysis of one or both 
hind limbs, forelimb weakness or paralysis; 6 = 
moribund. Functional data were pooled from two 
different experiments. 
EAE onset was considered on the day animals 
showed the first signs of disease (EAE score 0, 5 or 1; 
around day 9-10 post-immunization). Disease peak 
was considered on the day EAE score did not increase 
from the previous day (around day 15-17 post- 
immunization). Chronic phase of the disease was 
considered at day 21 post-immunization if EAE score 
decreased or was maintained with respect to disease 
peak. 
Drug administration 
Female C57Bl6/J mice were treated with daily 
intraperitoneal (i.p.) injections of 1 µg of native 
IL-3746-218 or the mutated monomeric forms IL-37D73K 
or IL-37Y85A in 200 µl of saline 28. Recombinant human 
IL-37 protein forms were administered when mice 
showed the first signs of the EAE disease, and then, 
daily until the end of the follow up. Control mice were 
treated with 200 µl of saline following the same 
protocol. Fingolimod was dissolved in distilled water 
and administered daily by oral gavage (0.3 mg/kg). 
Real-time Quantitative PCR Assay (qPCR) 
Total RNA was isolated from post-mortem 
human brain active MS lesions and normal appearing 
white matter (NAWM), as well as, from spinal cords 
harvested of EAE mice harvested at different stages of 
the disease using the RNeasy Lipid Tissue Mini Kit 
(Qiagen) following the manufacturer’s procedures. 
Total RNA was also extracted from PBMCs collected 
from MS patients and healthy donors using the 
QIAamp RNA Blood Tissue Mini Kit (Qiagen) 
according to the manufacturer’s guidelines. 
RNA was retrotranscribed using the cDNA 
Reverse Transcription Kit (Applied Biosystems). 
cDNA human libraries were analysed using a Bio-Rad 
CFX384 (CFX Manager V3.1) and TaqMan-designed 
primers (ThermoFisher Scientific) for the following 
human and mouse genes: IL37b (Hs00367201_m1), 
IL1R8 (Hs00222347_m1), IL1R5 (Hs00187256_m1), 
GAPDH (Hs02786624_g1), Gapdh (Mm03302249_g1), 
Il1r8 (Mm01275624_g1), Il1r5 (Mm00516053_m1). 
GAPDH/Gapdh was used as a housekeeping gene for 
human and mouse samples, respectively. All data 
were analysed using the 2ΔΔCt method. Data from 
EAE mice were pooled from two different 
experiments. 
Histological analysis 
Female hIL-37tg mice and WT littermates were 
euthanised 21 days post EAE induction with an 
overdose of pentobarbital sodium (Dolethal) and 
transcardially perfused with 4% paraformaldehyde 
(PFA) in 0.1 M of phosphate buffer (PB). Lumbar 
segments of spinal cord were harvested, post-fixed in 





4% PFA for 2 h on ice and cryoprotected in 30% 
sucrose in 0.1 M PB at 4ºC for at least 48 h. Next, 
spinal cords were embedded in Tissue-Tek®OTC 
(Sakura, Japan), sequential transversal sections (15 
µm-thick) between L3 and L5 segments were cut 
using a Leica cryostat and gelatine-coated glass slides. 
Samples were stored at –20ºC until further use. 
Spinal cord slides were stained with LFB (Sigma 
Aldrich). Briefly, after graded dehydration, sections 
were placed in 1 mg/mL of LFB solution in 96% 
ethanol and 0.05% acetic acid overnight at 37ºC and 
protected from light. Then, slides were washed with 
96% ethanol, rehydrated with distilled water and 
differentiated using a 0.5 mg/mL Li2CO3 solution in 
distilled water for 3-5 min at room temperature. 
Finally, sections were washed in distilled water, 
dehydrated again and mounted in DPX mounting 
medium (Sigma Aldrich). To assess the demyelinated 
area in the spinal cords, 6 random images per spinal 
cord were captured at 10X magnification with an 
Olympus DP73 Camera attached to an Olympus BX51 
microscope. The total demyelinated area in the spinal 
cord was measured with Image J image analysis 
software. Histological data were pooled from two 
different experiments. 
Cytokine protein expression assessment 
Female hIL-37tg mice and WT littermates were 
euthanised 3 days after the onset of EAE with and 
overdose of pentobarbital sodium (Dolethal) and 
transcardially perfused with 60 mL of sterile saline 
(0.9% NaCl). Spinal cords were harvested and rapidly 
frozen using liquid nitrogen. To assess the protein 
levels of cytokines, spinal cord were processed as we 
previously published 29. Briefly, tissue was 
homogenized in HEPES and the protein concentration 
determined with a DC Protein Assay (Bio-Rad). 
Protein homogenates were concentrated to 4 µg/µl 
and finally, protein levels of IL-4, IL-10, IL-1α, IL-1β, 
IL-6, TNF-α, IFNγ, IL-17A, CSF-3, CCL-5, CCL-2, 
CXCL-2 and CXCL-10 were analysed using a 
custom-designed Mouse Cytokine Magnetic Bead 
Panel (Affymetrix, eBioscience) on a Luminex- 
MAGPIX system (Millipore). Luminex data were 
obtained from a single experiment. 
Flow cytometry 
Female hIL-37tg mice and WT littermates were 
euthanised at peak of EAE with an overdose of 
pentobarbital sodium (Dolethal). 15 µl of blood was 
collected from a cardiac puncture and stored in 
heparinized vials at 4ºC. Then, mice were 
transcardially perfused with 60 mL of sterile saline 
(0.9% NaCl) and the spinal cords and lymph nodes 
(cervical and inguinal) were collected. 
To analyse the different immune cells, the spinal 
cord, blood and lymph nodes were processed as we 
previously described in [29]. Blood samples were 
incubated with red blood cell lysis buffer (BioLegend) 
according to manufacturer’ guidelines to obtain a cell 
suspension enriched in leukocytes. Spinal cord and 
lymph nodes were cut in small pieces and 
enzymatically dissociated incubating them 30 min at 
37ºC in 1 mL of HBSS without Ca2+/Mg2+ and 0.1% 
collagenase and 0.1% DNase. Next, samples were 
mechanically disintegrated by passing them with 
DMEM-10% FBS through a 70 µm cell strainer. After 
two washes, cell suspension was split into different 
1.5 mL microcentrifuge tubes according to the number 
of antibody combinations. For surface staining, 
samples were incubated with the following primary 
antibodies from eBioscience for 1 h at 4ºC in soft 
agitation at a 1:300 concentration: CD45-PerCP, 
CD11b-PE or PE-Cy7, F4/80-PE or -APC, Ly6C-FITC, 
Ly6G-PE, CD3-FITC-APC-PerCP; CD4-APC-Cy7, 
CD8-APC, CD49b-PE, CD24-PE and the isotype 
matched-controls (1:300 eBioscience). Samples were 
then fixed with 1% PFA. When needed, intracellular 
staining was done after extracellular staining and cell 
fixation. For this purpose, cells were first 
permeabilizated with Permeabilization Wash Buffer 
(Biolegend) or FoxP3 Transcription Factor Staining 
Buffer Set (eBioscience) for 30 min in case of doing 
FoxP3 staining. Cell were then incubated for 45 min at 
4ºC with FoxP3-PE-Cy7, tBet-PerCP, RORγ-APC, 
GATA3-PE, or the isotype matched-controls (1:300 
eBioscience) or unconjugated rabbit antibody against 
iNOS (1:100 Abcam) and unconjugated goat 
antibodies against Arg1 (1:100 Santa Cruz) followed 
by staining with Alexa488 or Alexa647 conjugated 
donkey secondary antibodies against rabbit or goat 
(1:500 Molecular Probes) or isotype matched-control 
for 45 min. Samples were finally analysed on a FACS 
Canto Flow Cytometer (BD Bioscience) and all data 
were processed using FlowJo® software V.10. Flow 
cytometry data were obtained from a single 
experiment. 
Haematopoiesis assay 
Bone marrow cells were obtained from femurs 
and tibia of WT and hIL-37tg mice after euthanasia. 
Cells were flushed out using a 21G-needle syringe 
with 5 ml of RPMI 1640 medium (ThermoFisher 
Scientific) supplemented with Penicillin/ 
Streptomycin (Sigma-Aldrich). Cells were passed 
through a 70 μm cell strainer (FisherBrand). Counts of 
monocytes, lymphocytes, and granulocytes were 
determined using a HemaTrue cell counter (Heska, 
Loveland, CO, USA). Before measuring, cell counter 
machine was calibrated using a certified blood control 





authorized by Heska. At least 3 measures of the same 
sample were performed, and average values were 
taken. 
Experimental design and statistical analyses 
All the experimental groups were gender- and 
age-matched. For all experiments, the number of mice 
used are stated in the figure legends and text. Data are 
shown as mean ± standard error of the mean (SEM). 
Statistical analysis was performed using GraphPad 
Prism 8. The distribution of the data was evaluated for 
normality using D’Agostino and Pearson test. Two 
tailed Student’s t test was used for the comparison 
between two different groups (human qPCR, 
histological analysis, cytokine levels, accumulation of 
immune cells). Mean clinical score follow-up was 
analysed by using two-way ANOVA repeated 
measures with post-hoc Bonferroni’s test for multiple 
comparisons. Differences were considered significant 
at p<0.05. 
Results 
Transgenic expression of IL37 reduces neuro-
logical deficits and protects against de-
myelination in the spinal cord of EAE mice 
Since the role of IL-37 in demyelinating diseases 
of the CNS is still poorly understood, we first sought 
to explore whether this cytokine exerted beneficial 
effects in EAE mice. Since the open frame of the IL37 
orthologue is not present in mice, we induced EAE in 
hIL-37tg mice and wildtype littermates (WT). We 
found that IL37 transcripts were detected at very low 
levels in the spinal cord of hIL-37tg at physiological 
conditions, but they were significantly increased (~7 
fold) at the peak and chronic phase of the disease, but 
not at its onset (Figure 1A). 
Knowing that the expression of IL37 was 
inducible in the spinal cord upon EAE induction, we 
next evaluated its contribution to disease. Female 
hIL-37tg mice were significantly protected against 
functional deficits compared to WT mice (Figure 1B). 
At the end of the follow up, hIL-37tg female mice 
showed a ~1.5 point reduction in EAE clinical score. 
Similar beneficial effects were observed in male 
hIL-37tg mice suffering from EAE. However, the 
onset of disease occurred significantly earlier in male 
mice expressing IL37 (Figure 1C). 
We then evaluated whether the enhancement in 
functional outcomes of female hIL-37tg mice after 
EAE induction was linked to myelin preservation. 
Histological analysis of lumbar spinal cords harvested 
at the end of the follow up (21 days post induction) 
revealed that the area of demyelination was indeed 
decreased ~50% in the hIL-37tg mice (Figure 1D-E). 
IL-37 attenuates inflammation in mice with 
EAE 
We next studied the anti-inflammatory actions of 
IL-37 in EAE. For this purpose, we first measured the 
protein levels of several cytokines in the spinal cord at 
day 3 after disease onset. A Luminex assay revealed 
that transgenic expression of IL-37 significantly 
reduced the protein levels of 5 pro-inflammatory 
 
 
Figure 1. The transgenic expression of IL37 protects against functional deficits and myelin loss in the spinal cord of mice with EAE. (A) Graph showing the 
levels of IL37 mRNA in the spinal cord of female hIL-37tg mice at different phase of EAE disease. (B) Clinical score of females and (C) male hIL-37tg mice and WT littermates. 
(D) Graph showing the quantification of the area of demyelination in the spinal cord of female hIL-37tg and WT littermates at 21 days post induction. (E) Representative images 
of lumbar spinal cord from female hIL-37tg mice and WT littermates at day 21 after EAE induction. *p<0.05; **p<0.01; ***p<0.001 vs. control. One-way ANOVA with Bonferroni 
post hoc test in A (n=7 per time point); Two-way repeated measures ANOVA with Bonferroni’s post hoc test in B (n=15 WT; n=14 hIL-37tg) and C (n=9 per group); Unpaired 
t-test in D (n=15 WT; n=14 hIL-37tg. Data were pooled from two different experiments. Data shown as mean±sem. 





cytokines (IL-1α, IL-1β, IL-6, TNFα and IFNγ), each of 
them linked to development of EAE pathophysiology 
(Figure 2A). Since cytokines coordinate the 
recruitment and activation of immune cells into the 
CNS parenchyma, we next evaluated whether 
transgenic expression of IL-37 reduced the 
accumulation of immune cells in the spinal cord at the 
peak of the disease. Flow cytometry analysis showed 
that hIL-37tg mice had significant lower numbers of T 
cells (CD3+), including CD4 and CD8 T cells, 
macrophages (CD45high, CD11b+, F4/80+), total 
microglial cells (CD45low, CD11b+) and activated 
microglial cells (CD45low, CD11b+, F4/80+) (Figure 
2B, Figure S1-S2). IL-37, however, did not attenuate 
the number of B cells (CD45+, CD11b–, CD3–, CD24+) 
and neutrophils (CD45+, CD11b+, F4/80–, Ly6G+) 
(Figure 2B, Figure S2B, F). Of note, transgenic 
expression of IL37 significantly reduced the 
proportion of pathogenic Th1 cells (CD3+, CD4+, 
tBet+) and increased the proportion of classical 
regulatory CD4 cells (CD3+, CD4+, FoxP3+) in the 
spinal cord (Figure 2C, Figure S3A). Moreover, IL-37 
reduced the expression of CD16/32+ and iNOS+ in 
macrophages by 20% (Figure 2D, Figure S3B), but did 
not alter the expression of Ly6C (Figure 2E, Figure 
S3C). These data indicate that IL-37 not only reduced 
the accumulation of immune cells in the spinal cord, 




Figure 2. IL-37 reduces the inflammatory response in the spinal cord of mice at the peak of EAE. (A) Protein level profile of cytokines (IL-4, IL-10, IL-1α, IL-1β, 
IL-6, IL-17A, IFNγ, TNFα and chemokines (CXCL-2, CXCL-10, CCL-2, CCL-5, CSF-3) in the spinal cord of female hIL-37tg relative to female WT at the peak EAE. (B) Number 
of infiltrated immune cells and (C) percentage of CD4+ T cells expressing the transcription factors CD49b, FoxP3, tBet, GATA3 or RORγ in the spinal cord of female WT and 
female hIL-37tg mice at the peak of EAE. (D) Percentage of macrophages expressing the pro-inflammatory markers CD16/32 and iNOS or (E) Ly6C in the spinal cord of female 
WT and female hIL-37tg mice at the peak of EAE. *p<0.05; **p<0.01; ***p<0.001 vs. WT. Unpaired t-test (n=5 per group in A; n=4 per group in B-E). Data were obtained from 
a single experiment. Data shown as mean±SEM. 






Figure 3. Effects of IL-37 on immune cell counts in the lymph nodes and blood in EAE mice. (A) Number of immune cells in the lymph nodes and (E) blood of female 
WT and female hIL-37tg mice at the peak of EAE. (B) Number of dendritic cells in the lymph nodes. (C) Percent of CD4+ T cells expressing CD49b, FoxP3, tBet, GATA3 or 
RORγ in lymph nodes and (F) blood. (D) Percentage of monocytes expressing Ly6C in lymph nodes and (G) blood. *p<0.05; **p<0.01; ***p<0.001 vs. WT. Unpaired t-test (n=4 
per group). Data were obtained from a single experiment. Data shown as mean±SEM. 
 
We then explored whether the reduced 
accumulation of immune cells in the spinal cord of 
hIL-37tg mice in EAE was due to a central or 
peripheral effect of this cytokine. Consequently, we 
first assessed the immune cell counts in the lymph 
nodes and blood at EAE disease peak. Similar to the 
spinal cord, flow cytometry analysis demonstrated 
that hIL-37tg mice featured a significantly reduced 
number of CD4 T cells (Figure 3A) but no changes in 
their phenotype (Figure 3B) in the lymph nodes, 
suggesting that IL-37 attenuated the expansion but 
not polarization of this T cell subset, respectively. 
IL-37 also reduced the number of macrophages and 
dendritic cells (CD45+, CD11b+, CD11c+) (Figure 3A), 
which is compatible with reduced T cell priming 
observed in the spinal cord (Figure 2B). The 
proportion of monocytes expressing Ly6C remained 
unaltered in lymph nodes (Figure 3C). In the blood 
samples, we found that IL-37 did not decrease the 
numbers of the different leukocyte populations 
(Figure 3D) but increased the proportion of non- 
classical regulatory CD4 T cells (Figure 3E) as 
reflected by increased CD49b expression. The 
proportion of monocytes expressing Ly6C remained 
unaltered in blood (Figure 3F). 
Finally, we performed a haematopoiesis assay to 
discard that the reduction in the number of immune 
cells in the CNS and the periphery was due to a lower 
basal progenitor number in the bone marrow of 
hIL-37tg. This assay revealed that transgenic 
expression of IL-37 did not alter lymphocytes, 
monocytes and granulocytes formation in the bone 
marrow (Figure S4). 






Figure 4. The protective role of IL-37 expression against EAE is mediated by the IL-1R8. A-B, Graphs showing the relative expression the Il1r5 (A) and Il1r8 (B) in 
the spinal cord of female EAE and naïve mice. (C-D), Clinical score of female WT, hIL-37tg, Il1r8 KO and hIL-37tg x Il1r8 KO mice showed as the mean clinical score (C), 
maximum and cumulative score (D). (E), Graph showing the quantification of myelin loss in the spinal cord of female WT, hIL-37tg, Il1r8 KO and hIL-37tg x Il1r8 KO mice at 21 
days post-induction. (F) Representative images of the spinal cords from each of the experimental groups. *p<0.05; **p<0.01; ***p<0.001 vs. WT. One-way ANOVA in A and B 
(n=6 in onset and n=7 in the other groups). Two-way ANOVA with repeated measures, Bonferroni’s post hoc test in C (n=21 in WT, n=16 in hIL-37tg, n=14, n=14 in Il1r8 KO 
and n=14 in hIL-37tg x Il1r8 KO. One-way ANOVA in D (n=21 in WT, n=16 in hIL-37tg, n=14 in Il1r8 KO and n=14 in hIL-37tg x Il1r8 KO. and E (n=20 in WT, n=16 in hIL-37tg, 
n=13 in Il1r8 KO and n=13 in hIL-37tg x Il1r8 KO. Data were pooled from two different experiments. Data shown as mean±SEM. 
 
IL-1R8 is critical for IL-37 to mediate beneficial 
effects in EAE 
As reported previously, IL-37 is a dual-function 
cytokine that can mediate its biological effects by 
acting as an extracellular cytokine [30] or by 
translocating to the nucleus [15, 31]. Here, we the 
sought to demonstrate the importance of the 
extracellular function of IL-37 in EAE. 
For this purpose, we first characterized the 
expression of IL-37 receptor complex in the spinal 
cord in different phases of EAE. We found that both 
components Il1r5 and Il1r8, were expressed in the 
spinal cord at physiological conditions and during 
EAE disease progression (Figure 4A and 4B), although 
Il1r5 transcripts significantly increased at peak and in 
chronic phase of EAE. 
Knowing that the components of the IL-37 
receptor complex were expressed in the spinal cord, 
we aimed at evaluating to what degree the 
extracellular IL-37 was important to mediate the 
beneficial effects of this cytokine in EAE. For this 
purpose, we crossed hIL-37tg mice with Il1r8 KO 
mice. We selected IL-1R8 for gene deletion to assess 
the importance of the extracellular IL-37 signalling 
instead of IL-1R5 because IL-1R8 is a unique 
co-receptor for IL-37. In contrast, IL-1R5 is also used 
by IL-18, and consequently, gene deletion of IL-1R5 
also alters IL-18 signalling. This double transgenic 
mouse (hIL-37tg x Il1r8ko) expresses the human form 
of IL-37b in the homozygous, but this cytokine has 
only nuclear function, since IL-1R8, which is crucial 
for the extracellular function of IL-37, has been 
genetically deleted.  
EAE induction in Il1r8 ko mice revealed that the 
lack of this receptor does not alter EAE pathogenesis. 
However, the beneficial effects of IL-37 were 
completely absent in hIL-37tg mice lacking Il1r8 
(Figure 4C-D). Accordingly, histological analysis 
revealed that the protective actions of IL-37 against 
demyelination were abrogated in the absence of Il1r8 
(Figure 4E-F). These experiments provide clear 
evidence that the extracellular function of IL-37 is 
crucial in conferring protection against EAE. 






Figure 5. The administration of recombinant human IL-37 protein in EAE mice. (A) Clinical score of female WT EAE mice treated with IL-3746-218, IL-37D73K, IL-37Y85A 
or vehicle showed as mean clinical score and as (B) maximum and cumulative score. (C) Graph showing the quantification of demyelinating areas in the spinal cord of female WT 
mice treated with native IL-3746-218, IL-37D73K, IL-37Y85A or vehicle and (D) representative images of these spinal cords. *p<0.05; **p<0.01; ***p<0.001 vs. vehicle. Two-way 
ANOVA with repeated measures, Bonferroni’s post hoc test in A (n= 9 per group in vehicle, IL-37D73K and IL-37Y85A and n=10 in native IL-3746-218). One-way ANOVA in B and C 
(n= 9 per group in vehicle, IL-37D73K and IL-37Y85A and n=10 in native IL-3746-218). Data were pooled from two different experiments Data shown as mean±SEM. 
 
Administration of recombinant human IL-37 
protein reduces neurological deficits and de-
myelination in EAE mice 
Since mice expressing IL-37 have less disease in 
the EAE model, we administered recombinant human 
IL-37 protein in EAE mice starting at disease onset. 
Since IL-37 form spontaneous dimers, which have 
reduced anti-inflammatory actions 28, 32, we 
compared the efficacy of the native IL-37 (IL-3746-218) 
to two mutant monomeric forms (IL-37D73K and 
IL-37Y85A), which do not dimerize. We found that 
daily administration of 1 µg of native IL-3746-218, 
IL-37D73K or IL-37Y85A from the onset of EAE enhanced 
functional outcomes and protected against 
demyelination (Figure 5A-D). Among the three 
recombinant IL-37 proteins, the mutant monomeric 
form IL-37D73K showed the greatest efficacy at both 
functional and histological levels, although not 
reaching statistical significance when compared to 
IL-3746-218 and IL-37Y85A (Figure 5A-D). Interestingly, 
we found that human recombinant IL-3746-218 protein 
led to similar therapeutic actions than Fingolimod, 
one of the most effective drugs to treat relapsing MS 
(Figure S5). 
Overall, these data support the therapeutic 
actions of exogenous administration of recombinant 
human IL-37 protein in EAE. 
IL37 is aberrantly induced in MS patients 
Since IL-37 plays a beneficial role in EAE, we 
finally evaluated IL-37 expression in MS patients. We 
assessed the expression of IL37 as well as IL-1R5 and 
IL-1R8 in PBMCs of MS patients and healthy controls. 
In addition, we examined brains samples from MS 
patients. qPCR analysis revealed that IL37 transcripts 
were barely detectable in PBMC from healthy 
controls, and that the levels of this anti-inflammatory 
cytokine were not significantly increased in MS 
patients (Figure 6A), although its receptor 
components were expressed (Figure 6B-C). However, 
IL37 was detectable albeit at very low levels in 
NAWM of MS brains. Strikingly, IL37 levels tended to 
decrease in MS active lesions, except in two of the 
patients who showed a marked increase in the 
transcripts for this cytokine (Figure 6D). In line with 
the PBMC data, IL1R5 and IL1R8 were also expressed 
in the NAWM of brain MS samples, and the level of 
IL1R5 tended to increase in active lesions (Figure 
6E-F). These data reveal that while the components of 
the IL-37 receptors are present in the PBMC and 
brains of MS individuals, there appears to be a 
paucity of IL-37 transcripts, indicative of a relative 
deficiency state. 
Discussion 
In the present study, we investigated whether 
the anti-inflammatory cytokine IL-37 protects hosts 
from EAE pathogenesis. We observed amelioration of 
the clinical signs of EAE and reduced demyelination 
in mice expressing human IL-37. The suppression of 
the inflammatory response correlates with a decrease 
in the protein levels of several pro-inflammatory 





cytokines in the spinal cord. Accordingly, IL-37 
reduces the number of CD4 T cells, macrophages and 
dendritic cells in the lymph nodes, and attenuates the 
accumulation of most of the immune cell populations 
into the CNS. Moreover, IL-37 switches the phenotype 
of CD4 T cells and macrophages in the CNS resulting 
in more regulatory and less inflammatory 
phenotypes. We also observed that the beneficial 
actions of IL-37 are mediated by signalling via its 
surface receptor complex IL-1R5/IL-1R8. Lastly, we 
provided a proof of concept that the administration of 
recombinant human IL-37 protein in EAE mice 
alleviates disease symptomatology and protects 
against demyelination. Thus, we hypothesise that this 
natural mechanism to attenuate inflammation might 
be aberrant in MS patients. 
IL-37 is a member of the IL-1 family that exerts 
potent anti-inflammatory action [33]. Although this 
cytokine is not present in mice, the generation of a 
transgenic mouse that expresses the human form of 
IL-37, and the use of recombinant human IL-37 
protein, have demonstrated its protective properties 
from a myriad of pathological challenges, such as 
colitis [34], metabolic syndrome and type 2 diabetes 
[18], lung inflammation [19], cancer [35], arthritis [36], 
calcific valve disease [37] and spinal cord injury [21]. 
In hIL-37tg mice, IL37 transcription is artificially 
regulated by a cytomegalovirus promoter, which is 
constitutively expressed in all the cells [9]. However, 
IL-37 is not constitutively expressed as expected in the 
hIL-37tg mouse due to the presence of an instability 
sequence in the mRNA that limits its half-life. 
Nonetheless, under inflammatory conditions, IL37 
mRNA is stabilized and, consequently, the translation 
of the protein is allowed [38]. Along this line and 
similar to previous findings [21], we found that IL37 
mRNA is present at very low levels in the spinal cord 
of hIL-37tg mouse at steady-state conditions but is 
markedly upregulated during EAE. Indeed, IL37 
mRNA reached the maximum expression at peak of 
EAE, a disease phase when leukocytes are highly 
accumulated in the spinal cord, which may suggest 
that leukocytes are the main source of this cytokine 
[39]. It is important to also note that IL37 expression 
was associated with reduced neurological 
impairments and demyelination of EAE mice, 
supporting the beneficial action of IL-37 in neuro-
inflammatory conditions, as we previously 
demonstrated in spinal cord injury [21]. 
It is well established that the cytokines produced 
by the initial wave of CNS-infiltrating leukocytes are 
the dominant force that orchestrates the ensuing 
inflammatory cascade in MS and EAE [40, 41]. These 
cytokines play a key role in the recruitment and 
activation of more immune cells from the circulation, 
as well as in the triggering of glial reactivity [41]; they 
are thus key contributors to MS pathology. In support 
of this concept, cytokines appear among the most 
associated risk factor genes for MS in genome-wide 
association study [42]. 
Here, we report that transgenic expression of 
IL37 silenced several pro-inflammatory cytokines in 
the spinal cord that have a key contribution to EAE 
and MS pathology [43–47]. The effects of IL-37 on 
cytokine levels were associated with reduced 
infiltration of immune cells into the spinal cord at the 
peak severity of the disease. This is quite relevant 
since leukocytes accumulate in demyelinating areas 
and their numbers correlate to tissue damage in MS 
patients and EAE mice [48, 49]. 
 
 
Figure 6. Characterization of the expression of IL37, IL1R5 and IL1R8 in PBMC and brain from healthy and MS patients. (A-F) Graphs showing the expression 
of IL-37 and the components of its extracellular receptor in PBMCs (A-C) and brain (D-F) from healthy and MS patients. Unpaired t-test in A, B and C (n=7 in healthy controls, 
n=11 in MS). Paired t-test in D, E and F (n=9 per group). Data shown as mean±SEM. 





Cytokines are also responsible for the 
polarization of immune cells, including T cells [41]. 
The increased proportion of T regulatory cells has 
been defined as a hallmark of the recovery phase in 
EAE mice [50] as well as, of the remission phase in 
RRMS individuals [51]. In this line, transgenic 
expression of IL37 reduced the percentage of 
pathogenic Th1 effector cells while increasing the 
percent of T regulatory cells in the spinal cord at the 
peak of the EAE disease. Importantly, we found that 
the polarizing effects of IL-37 were not restricted to 
CD4 T cells, since hIL-37tg mice also showed lower 
proportion of macrophages expressing CD16/32 and 
iNOS, which have potent pro-inflammatory effects 
and contribute to EAE pathology [52]. We also found 
decreased numbers of various immune cell 
populations in the lymph nodes of EAE mice with 
transgenic IL37 expression. For example, there was a 
~50% reduction in the number of dendritic cells, 
which are potent antigen-presenting cells endowed 
with the ability to prime T-cell responses. Both the 
number of MS plaques and the severity of EAE have 
been found to correlate with the presence and 
functional status of dendritic cells [53, 54]. The 
number of CD4 T cells was also significantly reduced 
in the lymph nodes of hIL-37tg mice, suggesting that 
the expansion of this T cell subset was attenuated by 
IL-37. However, this cytokine did not alter the 
phenotype of CD4 T cells in the lymph nodes. 
Similarly, IL-37 did not impede the efflux of immune 
cells into the circulation since the number of the 
different immune cells analysed did not change after 
its transgenic expression. However, IL-37 may have 
favoured the mobilization of regulatory CD4 T cells 
into the circulation since this immune cell subset was 
increased in the hIL-37tg mice after EAE. These data 
therefore suggest that the reduced accumulation of 
the immune cells in the spinal cord of EAE mice with 
transgenic expression of IL37 was likely due to the 
ability of this cytokine to reduce their infiltration into 
CNS rather than suppressing their mobilization into 
the circulation. 
IL-37 is a dual-function cytokine that can exert its 
anti-inflammatory activity through two different 
pathways: (i) the activation of the extracellular 
receptor complex IL-1R5/IL-1R8 or (ii) its 
translocation into the nucleus [14]. We here 
demonstrate that the interaction of IL-37 with its 
extracellular receptor complex is required to mediate 
its protective effects in EAE, by showing that the 
genetic deletion of IL-1R8, the co-receptor for IL-37, 
abolished its beneficial actions in EAE. It is important 
to note that this does not rule out the possibility that 
anti-inflammatory effects linked to the nuclear 
function of IL-37 likely take place in humans and may 
influence MS, as we recently observed in endotoxemia 
in mice [15]. 
Although IL-37 is up-regulated after 
inflammatory challenges there is accumulating 
evidence corroborating that IL-37 is deficient in some 
pathological conditions [37, 55–57]. A recent study 
revealed that the production of IL-37 by T cell is 
reduced in MS patients. In addition, in the same study 
the authors demonstrate that those patients who had 
higher levels of IL-37 in PBMCs were more protected 
against to the exacerbation of the disease than those 
with lower levels [22]. Although we did not observed 
reduction of IL-37 in PBMCs of MS patients, this 
cytokine was not up-regulated as compared to heathy 
volunteers. In this line, we also observed that IL-37 
was not upregulated in brain active lesions of most 
MS patients. Nonetheless, the components of the 
extracellular receptors for IL-37 were expressed in 
PBMCs and brain samples of healthy donors and MS 
patients. These data therefore suggest that although 
MS individuals have the machinery to activate this 
beneficial mechanism to contain inflammation, IL-37 
signalling is not properly induced due to low 
production of IL-37. Importantly, we showcase that 
the exogenous administration of recombinant human 
IL-37 protein in EAE mice ameliorated the clinical and 
histopathological signs of the disease, suggesting the 
therapeutic potential of IL-37 in MS. Highlight that 
treatment with recombinant IL-37 protein was 
initiated once mice showed the first clinical signs of 
EAE, which makes these findings clinically relevant. 
Recent studies have reported that IL-37 forms 
dimers with nanomolar affinity, resulting in limited 
bioactivity [32]. They uncovered that mutations in the 
dimer interface, such as IL-37D73K and IL-37Y85A, 
specifically disrupt dimer formation, resulting in 
stable monomers that provide greater suppression of 
inflammation compared with native IL-37 
(Eisenmesser et al., 2019). However, we did not find 
any significant enhanced effect of the two mutant 
monomers IL-37D73K and IL-37Y85A compared to the 
native IL-37 form, although the monomer IL-37D73K 
resulted in slight greater efficacy in EAE. This may 
indicate that the amount of IL-37 we administered 
was not high enough to favour the formation of 
dimers. Importantly, we found that human 
recombinant IL-37 protein exerted similar therapeutic 
potential than fingolimod, one of the most effective 
treatment for relapsing-remitting forms of MS. 
Interestingly, a recent study reported that serum 
levels of IL-37 were higher in MS individuals treated 
with fingolimod as compared to patients receiving no 
treatment, suggesting that this drug could exert its 
beneficial actions in MS, at least in part, by increasing 
the levels of this anti-inflammatory cytokine [22]. 





In conclusion, in the present study we provide 
clear evidence that IL-37 wields beneficial effects in 
EAE by signalling through the surface receptor 
complex IL-1R5/IL-1R8. Although further studies are 
needed to elucidate the precise role of IL-37 in MS 
patients, our data suggest that this cytokine could is a 
candidate for the treatment of MS patients. 
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